Document Detail

Extended-Infusion Eptifibatide to Prevent Stent Thrombosis in a Patient Undergoing Orthopedic Surgery (May).
MedLine Citation:
PMID:  21540405     Owner:  NLM     Status:  Publisher    
OBJECTIVE: To report the use of extended-infusion eptifibatide in a patient who had undergone placement of a drug-eluting stent and required repeat intervention of a hip fracture following mechanical failure. CASE SUMMARY: An 82-year-old female with an extensive history of coronary disease who had undergone placement of a drug-eluting stent was admitted following continued problems with her surgically repaired right hip. Radiographic imaging of the area revealed mechanical failure of the surgically repaired hip, requiring intervention. Clopidogrel and aspirin therapy was discontinued and intravenous eptifibatide 1 µg/kg/min was initiated prior to surgery; the drugs were then discontinued 4 hours before the procedure. During this admission, the patient received a total of 155 hours of eptifibatide to prevent acute coronary stent thrombosis while awaiting surgical intervention. Postoperatively, the patient experienced anemia and severe thrombocytopenia and required 11 units of packed red blood cells, but displayed no signs of stent thrombosis. DISCUSSION: Use of eptifibatide in this patient minimized the potential risk for stent thrombosis by reducing the interruption in antiplatelet therapy from 5 days, as is recommended for use with clopidogrel, to 4 hours. While this patient required several transfusions and experienced severe thrombocytopenia postoperatively, she recovered and had no cardiac-related problems. It is unclear whether the use of eptifibatide contributed to these complications, given the chronology of events. CONCLUSIONS: Extended-infusion eptifibatide appears to be an option for prevention of stent thrombosis in patients who require an interruption in antiplatelet therapy and are scheduled to undergo major orthopedic procedures. Careful consideration should be given regarding the risks and benefits of extended infusions of eptifibatide, as the potential for significant hemorrhage is a concern. Further research is warranted in this area.
Bryan D Lizza; Matthew J Kauflin
Related Documents :
21424885 - Boston type 1 keratoprosthesis for severe blinding vernal keratoconjunctivitis and moor...
21311985 - The impact of pretreatment assessment of oropharynx on interstitial soft palate radiofr...
21383565 - Factors associated with ileoanal pouch failure in patients developing early or late pou...
1880325 - Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy an...
16716615 - Continuous brachial plexus blockade in combination with the nmda receptor antagonist me...
15085895 - Mortality and long term morbidity in esophageal atresia: the reduced impact of low birt...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-3
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  -     ISSN:  1542-6270     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Grandview Medical Center, Dayton, OH.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current Treatment Strategies for Clozapine-Induced Sialorrhea (May).
Next Document:  Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.